Dernière mise à jour :
26/03/2024
Antibiotique   Vancomycin hydrochloride  
Injectable
Collyre Solution buvable
Stabilité des solutions Stabilité en mélange Facteur influençant la stabilité Compatibilités Voie d’administration Bibliographie Pdf
   Structure chimique  

Noms commerciaux   Noms commerciaux     

Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires

Amplobac Brésil
Anco L IV Turquie
Celovan Brésil, Inde, Pérou, Vénézuela
Dhacocin Malaisie
Edicin Pologne, Roumanie, Slovénie, Turquie
Estafimac Mexique
Estavam Mexique
Imvaco Chili
Kovan Chili
Rivervan Argentine
Tancofeto Colombie, Malaisie
Vacsol Mexique
Valcidem Mexique
Vamysin Belgique, Luxembourg
Vanaurus Colombie, Equateur
Vanbiotic Colombie, Equateur
Vancam Mexique
Vancobact Egypte
Vancobiotic Pérou
Vancocare Inde
Vancocin Arabie Saoudite, Australie, Autriche, Canada, Emirats Arabes Unis , Etats Unis d’Amérique, Grande Bretagne, Hongrie, Inde, Irlande, Luxembourg, Pays bas, Pologne, Suède, Suisse
Vancocina Brésil, Italie
Vancofar Pérou
Vancogen Inde
Vancoled Emirats Arabes Unis , Inde
Vancolon Arabie Saoudite, Egypte, Emirats Arabes Unis
Vancomate Inde
Vancomax Argentine, Equateur, Iran, Pérou
Vancomicina Argentine, Chili, Colombie, Equateur, Espagne, Italie, Mexique, Portugal, Roumanie, Tunisie
Vancomix Egypte
Vancomycin Allemagne, Arabie Saoudite, Australie, Autriche, Canada, Danemark, Egypte, Emirats Arabes Unis , Etats Unis d’Amérique, Finlande, Grande Bretagne, Grèce, Hongrie, Irlande, Islande, Norvège, Nouvelle Zélande, Suède
Vancomycine Belgique, Egypte, France, Luxembourg, Maroc, Pays bas, Suisse
Vanconat Inde
Vanconor Pérou
Vancorin Inde, Malaisie, Turquie
Vancosan Allemagne, Grèce
Vancoser Inde
Vancotek Turquie
Vancotex Italie
Vancox Mexique
Vankomisin Turquie
Vanlid Inde, Malaisie, Vénézuela
Varedet Argentine, Colombie, Equateur, Pérou
Yestafhal Mexique
Zengac Italie
Bibliographie   Injectable   Bibliographie : Vancomycin hydrochloride  
Type Source
3 Revue Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59 Revue Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
63 Revue Marquardt Ed, Lam SSY.
Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 811-812.
73 Revue Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159.
81 Revue Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Revue Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
85 Revue Trissel LA, Bready BB.
Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 1716-1719.
91 Revue Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210.
93 Revue Hutchings SR, Rusho WJ, Tyler LS.
Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery.
Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
94 Revue Chandler SW, Folstad J, Trissel LA.
Aztreonam-vancomycin incompatibility.
Am J Hosp Pharm 1990 ; 47: 1970.
95 Revue Pritts D, Hancock D.
Incompatibility of ceftriaxone with vancomycin.
Am J Hosp Pharm 1991 ; 48: 77.
99 Revue Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
129 Revue Smythe M, Malouf E.
Visual compatibility of insulin with secondary intravenous drugs in admixtures.
Am J Hosp Pharm 1991 ; 48: 125-126.
132 Revue Najari Z, Rusho WJ.
Compatibility of commonly used bone marrow transplant drugs during Y-site delivery.
Am J Health-Syst Pharm 1997 ; 54: 181-184.
150 Revue Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35.
169 Revue Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
176 Revue Mantong ML, Marquardt ED.
Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182 Revue Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
186 Revue Swart EL, Mooren RAG, Van Loenen AC.
Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198 Revue Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
244 Revue Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Revue Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Revue Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253 Revue Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528.
260 Revue Szof C, Walker PC.
Incompatibility of cefotaxime sodium and vancomycin sulfate during Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2054, 2057.
264 Revue Leboucher G, Charpiat B.
Incompatibilité physico-chimique entre l’oméprazole et la vancomycine.
Pharm Hosp Fr 1997 ; 121: 124.
266 Revue Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
280 Revue Allen LV, Stiles ML, Prince SJ, Sylvestri MF.
Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 2427-2433.
284 Revue Trissel LA, Xu QA, Martinez JF.
Compatibility and stability of aztreonam and vancomycin hydrochloride.
Am J Health-Syst Pharm 1995 ; 52: 2560-2564.
299 Revue Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Revue Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Revue Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Revue Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
315 Revue Bahal SM, Lee TJ, McGinnes M, Dobler GL.
Visual compatibility of warfarin sodium injection with selected medications and solutions.
Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
316 Revue Veltri M, Lee CKK.
Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs.
Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
317 Revue Kershaw BP, Monnier HL, Mason JH.
Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration.
Am J Hosp Pharm 1993 ; 50: 1360-1362.
334 Revue Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Revue Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
336 Revue Forman JK, Lachs JR, Souney PF.
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.
Am J Hosp Pharm 1987 ; 44: 1408-1409.
337 Revue Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533.
384 Revue Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 630-632.
385 Revue Benedict MK, Roche VF, Banakar UV, Hilleman DE.
Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1117-1118.
386 Revue Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1357-1358.
402 Revue Savitsky ME.
Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 820-821.
405 Revue Nieves-Cordero AL, Luciw HM, Souney PF.
Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1985 ; 42: 1108-1109.
428 Revue Nahata MC, Miller MA, Durrell DE.
Stability of vancomycin hydrochloride in various concentrations of dextrose injection.
Am J Hosp Pharm 1987 ; 44: 802-804.
430 Revue Das Gupta V, Stewart KR, Nohria S.
Stability of vancomycin hydrochloride in 5% dextrose and 0.9% sodium chloride injections.
Am J Hosp Pharm 1986 ; 43: 1729-1731.
479 Revue Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966.
491 Revue Turowski RC, Durthaler JM.
Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2181-2184.
492 Revue Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
496 Revue Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
552 Revue Martinez JF, Trissel LA, Gilbert DL.
Compatibility of warfarin sodium with selected drugs and large-volume parenteral solutions.
Int J Pharm Compound 1997 ; 1: 356-358.
604 Laboratoire Stabilité des médicaments dans l'Intermate® SV50, 100, 200
Baxter 1998
654 Revue Allen LV.
Stability of vancomycin hydrochloride in Medication Cassette* reservoirs.
Int J Pharm Compound 1997 ; 1: 123-124.
660 Revue Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
694 Revue Walker SE, Birkhans B.
Stability of intravenous vancomycin.
Can J Hosp Pharm 1988 ; 41: 233-238, 242.
702 Revue Biellmann-Berlaud V, Willemin JC.
Stability of vancomycin in polyolefine or PVC bags and glass vials.
J Pharm Clin 1998 ; 17: 145-148.
889 Revue Janknegt R, Stratermans T, Cilissen J, Lohman JJHM, Hooymans PM.
Ofloxacin intravenous. Compatibility with other antibacterial agents.
Pharm Weekbl [Sci] 1991 ; 13: 207-209.
891 Revue Matsuura G.
Visual compatibility of sargramostim (GM-CSF) during simulated Y-site administration with selected agents.
Hosp Pharm 1992 ; 27: 200, 202, 209.
895 Revue Yao JDC, Arkin CF, Karchmer AW.
Vancomycin stability in heparin and total parenteral nutrition solutions: novel approach to therapy of central venous catheter-related infections.
JPEN 1992 ; 16: 268-274.
905 Revue Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
913 Revue Wood MJ, Lund R, Beavan M.
Stability of vancomycin in plastic syringes measured by high-performance liquid chromatography.
J Clin Pharm Ther 1995 ; 20: 319-325.
921 Revue Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
931 Revue Galanti LM, Hecq JD, Vanbeckbergen D, Jamart J.
Long-term stability of vancomycin hydrochloride in intravenous infusions.
J Clin Pharm Ther 1997 ; 22: 353-356.
939 Revue Gilbar PJ, Groves CF.
Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection.
Aust J Hosp Pharm 1994 ; 24: 167-170.
966 Revue Martins AM, McDougal A, Hamilton D, Igwemezie L, McErlane K.
In vitro assessment of vancomycin HCl compatibility after coinfusion with a specialized amino acid formulation.
JPEN 1991 ; 15: 536-539.
999 Revue Watson D.
Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution.
JPEN 1985 ; 9: 220-224.
1047 Revue Souney PF, Colucci RD, Mariani G, Campbell D.
Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1984 ; 41: 323-324.
1057 Revue Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072 Revue Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1135 Revue Baltz JK, Kennedy P, Minor JR, Gallelli J.
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1990 ; 47: 2075-2077.
1167 Revue Grennberg RN, Saeed AM, Kennedy DJ, McMillian R.
Instability of vancomycin in infusaid drug pump model 100.
Antimicrob Agents Chemother 1987 ; 31: 610-611.
1201 Revue Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG.
Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures.
Am J Hosp Pharm 1981 ; 38: 1919-1922.
1315 Revue Halpern NA, Colucci RD, Alicea M, Greenstein R.
Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1399 Revue Cairns CJ, Robertson J.
Incompatibility of ceftazidime and vancomycin.
Pharm J 1987 ; 238: 577.
1410 Revue Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1414 Revue Mayer JLR, Pascale VJ, Clyne LP, Malkus H, Santos FS, van Hoff J.
Stability of low-dose vancomycin hydrochloride in heparin sodium 100 UI / ml.
J Pharm Technol 1999 ; 15: 13-17.
1415 Revue Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1416 Revue Stamatakis MK, Leader G, Tracy TS.
Stability of high-dose vancomycin and ceftazidime in peritoneal dialysis solutions.
Am J Health-Syst Pharm 1999 ; 56: 246-248.
1423 Revue Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1490 Revue Halpern NA, Colucci RD, Alicea M, Greenstein R.
The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1508 Revue Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
1611 Revue Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506.
1614 Revue Trissel LA, Xu QA, Zhang Y, Saenz CA, Ingram DS.
Stability of ciprofloxacin and vancomycin hydrochloride in autodose infusion system bags.
Hosp Pharm 2001 ; 36: 1170-1173.
1625 Revue Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1649 Revue Gilbar P, McAllan Z.
Ticarcillin-potassium clavulanate and vancomycin incompatibility.
Aust J Hosp Pharm 1997 ; 27: 470.
1671 Revue Khalfi F, Dine T, Gressier B, Luyckx M, Brunet C, Ballester L, Goudaliez F, Cazin M, Cazin JC.
Compatibility and stability of vancomycin hydrochloride with PVC infusion material in various conditions using stability-indicating high-performance liquid chromatographic assay.
Int J Pharm 1996 ; 139: 243-247.
1674 Revue Trissel LA, Gilbert DL, Martinez JF.
Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 1515-1522.
1712 Revue Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 Revue Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Revue Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1748 Revue Wang DP, Wang MT, Wong CY, Lee DKT.
Compatibility of vancomycin hydrochloride and famotidine in 5% dextrose injection.
Int J Pharm Compound 1997 ; 1: 354-355.
1754 Revue Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1759 Revue Servais H, Tulkens PM.
Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients.
Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
1802 Revue Bell MS, Nolt DH.
Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery.
Am J Health-Syst Pharm 2003 ; 60: 193-194.
1803 Revue Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1868 Revue Husson E, Crauste-Manciet S, Hadj-Salah E, ,Segier JC, Broissard D.
Stabilité galénique de mélanges commercialisés de nutrition parentérale en présence de médicaments: médicaments dans le mélange.
Nutr Clin Metab 2003 ; 17: 8-14.
1871 Revue Sautou-Miranda V, Libert F, Grand-Boyer A, Gellis C, Chopineau J.
Impact of deep freezing on the stability of 25 mg/ml vancomycin ophtalmic solutions.
Int J Pharm 2002 ; 234: 205-212.
1877 Revue Lifshitz T, Lapid-Gortzak R, Finkelman Y, Klemperer I.
Vancomycin and ceftazidime incompatibility upon vitreal injection.
Br Ophtalmol 2000 ; 84: 117.
1925 Revue Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953 Revue Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1959 Revue Mac Lellan C, Papadopoulos A.
Precipitate formation after subconjonctival administration of ceftazidime and vancomycin.
Hosp Pharm 2005 ; 40, 2: 154-155.
1982 Revue Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2034 Revue Rodenbach MP, Hecq JD, Vanbeckbergen D, Jamart J, Galanti L.
Effect of freezing, long-term storage and microwave thawing on the stability of vancomycin hydrochloride in 5% dextrose infusions.
EJHP Science 2005 ; 11, 5: 111-113.
2037 Revue Robinson JL, Tawfik G, Saxinger L, Stang L, Etches W, Lee B.
Stability of heparin and physical compatibility of heparin/antibiotic solutions ...
J Antimicrob Chemother 2005 ; 56: 951-953.
2087 Revue Ferreira E, Forest JM, Hildgen P.
Compatibility of dimenhydrinate injectable by Y administration.
Pharmactuel 2004 ; 37: 17-20.
2090 Revue Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2109 Revue Pelletier E, Forest JM, Hildgen P.
Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels.
Pharmactuel 2006 ; 39: 71-75.
2139 Revue Serrurier C, Chenot ED, Vigneron J, May I, Demor? B.
Assessment of injectable drug’s administration in two intensive care units and determination of potential physico-chemical incompatibilities.
EJHP Science 2006 ; 12,5: 96-99.
2141 Revue Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM.
Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.
J Antimicrob Chemother 2003 ; 51: 651-658.
2147 Revue Nornoo AO, Elwell RJ.
Stability of vancomycin in icodextrin peritoneal dialysis solution.
Ann Pharmacotherapy 2006 ; 40, 11: 1950-1954.
2173 Revue Grioffiths W, Favet J, Ing H, Sadeghipour F, Bonnabry P.
Chemical stability and microbiological potency of intravenous vancomycin hydrochloride syringes for use in the neonatal intensive care.
EJHP Science 2006 ; 12, 6: 135-139.
2192 Revue Cochran BG, Sowinski KM, Fausel C, Overholser BR.
Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs.
Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414.
2228 Revue Kupiec T, Ben M, Trusley C, Trissel LA.
Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated Y-site administration.
Int J Pharm Compound 2008 ; 12,2: 170-173.
2231 Revue de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S.
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2233 Revue Condie C.K, Tyler L.S, Barker B, Canann D.M.
Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery
Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247 Revue Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262 Revue Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2335 Revue Canann D, Tyler L.S, Barker B, Condie C.
Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients
Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
2370 Revue Mawhinney WM, Adair CG, Gorman SP, McClurg B.
Stability of vancomycin hydrochloride in peritoneal dialysis solution
Am J Hosp Pharm 1992 ; 49: 137 - 139.
2375 Revue Strong DK, Ho W, Nairn JG.
Visual compatibility of vancomycin and heparin in peritoneal dialysis solutions
Am J Hosp Pharm 1989 ; 46: 1832 - 1833.
2475 Revue Wade J, Cooper M, Ragan R.
Simulated Y-Site Compatibility of Vancomycin and Piperacillin-Tazobactam
Hosp Pharm 2015 ; 50: 376-379.
2530 Revue Bartoll A, Bellés Medall M, Peñarrocha J, Escrig L, Clemente R, Azuara J.
Physicochemical and Microbiological Stability of Vancomycin 10-mg/mL Intravitreal Syringes.
Int J Pharm Compound 2022 ;26,4:330-335
3012 Revue Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3101 Revue Wazny LD, Blake PG.
Incompatibility of Vancomycin and Ceftazidime for Intraperitoneal Use.
Perit Dial Int 2002 ; 22: 93-94.
3120 Poster Maillot-Pyszczek V, Bourdeaux D, Sautou V, Chopineau J.
Etude de stabilité de solutions intravitréennes de vancomycine à 10 mg/ml.
Congrès HOPIPHARM 2010
3122 Revue Dotson B, Lynn S, Savakis K, Churchwell MD.
Physical compatibility of 4% sodium citrate with selected antimicrobial agents.
Am J Health-Syst Pharm 2010 ; 67: 1195-1198.
3125 Revue Baker D S, Waldrop Bruce, Arnold John.
Compatibility and Stability of Cefotaxine, Vancomycin, and Ciprofloxacin in Antibiotic Lock Solutions Containing Heparin.
Int J Pharm Compound 2010 ; 14, 4: 346-349.
3201 Revue Dice JE.
Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit.
J Pediatr Pharmacol Ther 2006 ; 11:233?6.
3216 Revue Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18
3327 Revue LaPlante K.L, Woodmansee S, Mermel L.A.
Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions.
Am J Health-Syst Pharm 2012 ; 69:1405-1409
3365 Revue Nichols K.R, DeMarco M.W, Vertin M.D, Knoderer C.A.
Y-Site Compatibility of Vancomycin and Piperacillin/Tazobactam at Commonly Utilized Pediatric Concentrations.
Hosp Pharm 2013 ; 1: 44-47
3385 Revue Raverdi V, Ampe E, Hecq JD, Tulkens PM.
Stability and compatibility of vancomycin for administration by continuous infusion.
J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408 Revue Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3421 Revue Leung E, Venkatesan N, Ly S.C, Scheetz M.H.
Physical compatibility of vancomycin and piperacillin sodium–tazobactam at concentrations typically used during prolonged infusions.
Am J Health-Syst Pharm 2013 ;70:1163-1166.
3428 Revue Nichols K.R, DeMarco M.W, Vertin M.D, Knoderer C.A.
Y-site compatibility of vancomycin and piperacillin/tazobactam at commonly utilized pediatric concentrations.
Hosp Pharm 2013 ; 48, 1: 44-47.
3485 Revue Huey-Ping Ng, Kwong-Fah Koh, Lai-San Tham.
Vancomycin causes dangerous precipitation when infused with gelatin fluid.
Anaesthesia 2000 ; 55, 10: 1039-1040.
3523 Laboratoire Ceftriaxone (Rocephin®) - Summary of Product Characteristics.
Roche 2018
3539 Laboratoire Bivalirudin (Angiox®) - Summary of Product Characteristics.
The Medecines Company 2013
3540 Laboratoire Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3542 Revue Berti A.D, Hutson P.R, Schulz L.T, Webb A.P, Rose W.E.
Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion
Am J Health-Syst Pharm 2015 ; 72:390-395
3543 Laboratoire Ceftazidime – Summary of Product Characteristics
Wockhardt 2013
3548 Laboratoire Cefepime (Maxipime®) - Summary of Product caracteristics.
Bristol Myers Squibb 2007
3557 Revue Chan A, Tawfik G, Cheng W.
Physical Incompatibility between Parenteral Cloxacillin and Vancomycin.
Can J Hosp Pharm 2013 ; 66, 5: 310-312
3564 Laboratoire Rocuronium B Braun - Résumé des caractéristiques du produit.
B Braun 2012
3571 Revue Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M.
Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration.
Hosp Pharm 2014 ; 49, 1: 42-47.
3588 Laboratoire Vancomycine (Vancocin®) - Résumé des caractéristiques du produit
Sandoz 2011
3662 Laboratoire Foscavir (Foscarnet®) - Summary of Product Characteristics
Clinigen 2014
3668 Laboratoire Dexamethasone - Summary of Product Characteristics
Hospira 2015
3728 Revue Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3767 Revue Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172.
3791 Poster Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.
Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.
Apifh Congress, Paris November 2014 2014
3813 Revue Teibel H.M, Knoderer C.A, Nichols K.R.
Compatibility of Vancomycin and Oxacillin During Simulated Y-Site Delivery.
Hosp Pharm 2015 ; 50, 8: 710-713.
3824 Revue Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3827 Poster Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Poster Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3841 Revue Nicholas O?Donnell J, Venkatesan N, Manek M, Rhodes N.J, Scheetz M.H.
Visual and absorbance analyses of admixtures containing vancomycin and piperacillin–tazobactam at commonly used concentrations.
Am J Health-Syst Pharm 2016 ; 73:241-246
3883 Laboratoire Ceftazidime - Résumé des caractéristiques du produit
Arrow 2016
3888 Revue Ranganathan D, Naicker S,. Wallis S.C, Lipman J, . Ratanjee S.K, Roberts J.A
Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (STAB Study).
Perit Dial Int 2016 ; 36:421-426.
3948 Revue Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P .
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.
JPEN 2012 ;30. 416?424.
3951 Revue Battistella M, Walker S, law S, Lok C.
Antibiotic lock: In vitro stability of vancomycin and four percent sodium citrate stored in dialysis catheters at 37°C
Hemodial Int 2009 ; 13, 3: 322-328.
3956 Revue Bastani B; Amin K; Herr A.
Prolonged Stability of Stored Vancomycin, Gentamicin, and Heparin for Use in the Antibiotic-Lock Technique.
ASAIO Journal 2005 ; 51,6:761-763.
3958 Revue Henrickson K.J; . Powell K.R; . Schwartz C.L.
A Dilute Solution of Vancomycin and Heparin Retains Antibacterial and Anticoagulant Activities .
J Infect Dis 1988 ; 157, 3: 600-601.
3960 Revue Kufel W.D, Miller C.D, Johnson P.R, Reid K., Zahra J.J, Seabury R.W.
Y-site Incompatibility Between Premix Concentrations of Vancomycin and Piperacillin-Tazobactam: Do Current Compatibility Testing Methodologies Tell the Whole Story?
Hosp Pharm 2017 ;52,2:132-137.
3964 Revue Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
3976 Revue Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
3984 Revue Meyer K, Santarossa M, Danziger L.H, Wenzler E.
Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water.
Hosp Pharm 2017 ,52;3 : 221-228
3985 Poster Manai M., Soussi M.A., Lazreg O., Drira C., Ben Tekaya S. et Razgallah Khrouf M.
Compatibilité physique entre médicaments injectables et nutrition parentérale pédiatrique : Evaluation in-vitro.
Hopipharm Congress 2017 - Nancy 2017
3997 Revue Katip W.
Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74:14 : 1099-1102
4007 Poster Masse M, Genay S, Carta N, Delannoy-Rousseli?re C, Moreau F, Barthelemy C, Faure K, Decaudin B, Odou P.
Etude de la stabilité de la vancomycine à 40 mg/ml au cours d'une perfusion de 24 heures.
Hopipharm Congress 2017-Nancy 2017
4027 Revue Wei Y, WonJoon Yang J, Boddu S, Jung R, Churchwell M.
Compatibility, Stability, and Efficacy of Vancomycin Combined With Gentamicin or Ethanol in Sodium Citrate as a Catheter Lock Solution.
Hosp Pharm 2017 ;52,10:685-690
4055 Revue Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4089 Revue Godet M, Simar J, Closset M, Hecq J.D, Braibant M, Soumoy L, Gillet P, Jamart J, Bihin B, Galanti L.
Stability of Concentrated Solution of Vancomycin Hydrochloride in Syringes for Intensive Care Units.
Pharmaceutical Technology in Hospital Pharmacy 2018 ;3,1:23-30
4128 Poster Masse M, Genay S, Carta N, Moreau F, Delannoy-Rousselière C, Barthélémy C, Décaudin B, Faure K, Odou P.
Stabilité de la vancomycine à des doses méningées dans les seringues au cours d'une perfusion de 24 heures.
GRITA Symposium Perfusion 2017, Lille, France. 2017
4145 Revue Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4254 Revue D'Huart E, Vigneron J, Demoré B.
Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs
Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4319 Revue Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4348 Revue D'Huart E, Vigneron J, Charmillon A, Clarot I, Demoré B.
Physicochemical Stability of Vancomycin at High Concentrations in Polypropylene Syringes.
Can J Hosp Pharm 2019 ;72(5):360-8
4354 Poster Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.
Compatibilité visuelle du Vyxeos lors d'administration en Y avec une sélection de médicaments injectables.
GERPAC Congress 2019 2019
4373 Revue Masse M, Genay S, Martin Mena A, Carta N, Lannoy D, Barthélémy C, Décaudin B, Odou P.
Evaluation of the stability of vancomycin solutions at concentrations used in clinical services.
EJHP 2020 ; 27(e1):e87-e92.
4380 Laboratoire Posaconazole (Noxafil®) - Summary of Product Characteristics
Merck Sharp & Dohme Limited 2019
4419 Revue Holt R.J, Siegert S.W.K, Krishna A.
Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection.
J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4434 Revue Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4440 Revue Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M.
Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion.
Ann Nutr Metab 2018 ; 73: 227-233.
4470 Revue Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P.
Continuous versus intermittent infusion of temocillin in intensive care unit patient.
Critical care 2005 ; 9(Suppl 1) P37
4488 Revue Nezvalova-Henriksen K, Niklas Nilsson N, Tomine Østerberg C, Staven Berge V, Tho I.
Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care.
Pharmaceutics 2020 ; 12, 677.
4524 Poster Stucki C, Sautter A-M, Bonnabry P.
Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology.
ESCP Symposium, Geneva, Switzerland 2009
4528 Revue Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4543 Revue Senarathna G, Strunk T, Petrovski M, Batty K.
Physical compatibility of pentoxifylline and intravenous medications.
Archives of Disease in Childhood 2018 ;104:292–295.
4569 Revue Lee T.M , Villareal C.L, Meyer L.M.
Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications.
Hosp Pharm 2021 ; 56, 4: 282-286.
4603 Revue Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4634 Revue Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A.
Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy.
Antibiotics 2022 ;11,4: 458
4654 Poster Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.
Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables.
Communication personnelle 2021
4655 Revue Holyk A, Lindner A, Lindner S, Shippert B
Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration.
Am J Health-Syst Pharm 2022 ;79,1:27-33
4698 Revue Ayari G, D'Huart E, Vigneron J, Demoré B.
Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs.
Pharmaceutical Technology in Hospital Pharmacy 2022
4742 Revue Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales